Zhitong Finance App News, Kanghua Biotech (300841.SZ) announced that the company (Party B) has reached an agreement with Sichuan Biomedical Group Pharmaceutical Industry Group Co., Ltd. (“Sichuan Biomedical Group” or “Party A 1”), Sichuan Development Leading Capital Management Co., Ltd. (“Leading Capital” or “Party A 2”) to establish a strategic partnership between parties A and B to jointly promote cooperation in the biomedical industry, and recently signed a “Strategic Cooperation Agreement”.

According to the agreement, Party A and Party B will cooperate closely to actively expand novel vaccine technology routes in the field of cutting-edge innovative vaccines, carry out R&D exploration in business technology fields such as mRNA technology platforms, recombinant protein nanoparticle technology, multivalent vaccines and novel adjuvant systems, enrich the variety of vaccine products, and cooperate to build a cutting-edge biotechnology platform for biological vaccines, integrating cutting-edge bioengineering technology, artificial intelligence, big data analysis and automation systems to create an efficient, intelligent and accurate vaccine R&D and production ecosystem to help innovate and break through vaccine technology and enhance products Safety and efficacy, ensure public health, maintain public health safety, and promote the upgrading and development of the vaccine industry in Sichuan Province.

The announcement stated that the signing of this agreement can promote the establishment of a harmonious and close strategic partnership between the two parties, facilitate the sharing of superior resources and complementary advantages, effectively enhance the company's ability to operate continuously, and enhance the company's market position and comprehensive competitive strength.